Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

GENERIC SUBSTITUTION FOR DRUGS WITH EXCLUSIVE INDICATIONS poses no risk to pharmacists of liability or loss of liability insurance coverage, the National Association of Pharmaceutical Manufacturers (NAPM) contended in a Dec. 30 letter to a California-based pharmacy group, Pharmacists Planning Services, Inc. (PPSI). NAPM was responding to a "Generic Alert" memorandum and a subsequent newsletter, which was mailed by PPSI to its members, which warned that pharmacists could face a liability risk for substituting generic propranolol for Ayerst's Inderal, when it is prescribed for post-myocardial infarction patients. Not only do PPSI's views "have absolutely no legal basis," but they were disseminated after the group had been advised that they are "incorrect as a matter of law," NAPM charged. PPSI's assertion was based on the grounds that only Inderal is labeled for the post-infarction indication ("The Pink Sheet" Sept. 30, T&G-5). NAPM demanded an "immediate and complete retraction in a manner that is reasonably calculated to reach all those to whom the original advice was rendered." PPSI's statements that such substitution for Inderal poses a civil liability risk and that liability insurance will not cover such cases are "intended to frighten pharmacists into avoiding substitution of not only generic propranolol, but generic drugs generally," the association maintained. "The only reason" generic propranolol labeling differs from Inderal's is that under the 1984 ANDA/patent restoration law, "certain new indications approved for existing products between Jan. 1, 1982 and Sept. 24, 1984 are available exclusively until Sept. 24, 1986 (two years from the date of passage of the act) for the product" that received the new indication, NAPM explained. "On Sept. 24, 1986, however, all generic propranolol products, without necessitating any change whatsoever in formulation, dosage, strength or manner of manufacture, will be able to" print labels that include the post-infarction indication," the association said. Rep. Waxman (D-Calif.), one of the congressional authors of the ANDA/patent law indicated to PPSI in a Nov. 25 letter that "the information provided in the 'Generic Alert' letter was substantially and significantly incorrect," NAPM said. "In essence," Waxman's letter indicated "that pharmacists did not face increased risk of liability or loss of liability insurance for the dispensing of generic propranolol regardless of the indication for which the drug was prescribed," the association maintained. After receiving Waxman's opinion letter, PPSI issued its newsletter "essentially" repeating the views earlier expressed in the "Generic Alert," NAPM asserted. "In our view the information you are providing regarding the substitution of generic propranolol is disparaging of generic propranolol (and generic drugs in general) and was published and distributed with knowledge that it was incorrect," NAPM said.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts